Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Diego Andrey², Christoph Berger³, Axel Finckh², Pierre Lescuyer², Adrian Ciurea⁴, Tanja Maletic¹, Christos Polysopoulos¹, Myriam Riek¹, Almut Scherer¹, Kim Lauper², Burkhard Moeller⁵, Judith Safford⁶, Sandra Schweizer⁷, Isabell von Loga¹, Nicolas Vuilleumier⁸ and Andrea Rubbert-Roth⁹, ¹SCQM Foundation, Zurich, Switzerland, ²Geneva University Hospital, Geneva, Switzerland, ³University Hospital Basel, Basel, Switzerland, ⁴University Hospital Zurich, Zrich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶RheumaCura Foundation, Zurich, Switzerland, ⁷Swiss League Against Rheumatism, Zurich, Switzerland, ⁸University Hospital of Geneva, Geneva, Switzerland, ⁹Kantonspital St Gallen, St.Gallen, Switzerland
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…
Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: L10 • ACR Convergence 2021
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
joshua solomon¹, Felix Woodhead², Sonye Danoff³, Shana Haynes-Harp⁴, Tanvi Naik⁵, Cathie Spino⁵, Shelley Hurwitz⁶, Rie Maurer⁶, Daniel Chambers⁷, Martin Kolb⁸, Hiliary Goldberg⁶ and Ivan Rosas⁴, ¹National Jewish Health, Denver, CO, ²University of Leicester, Leicester, United Kingdom, ³Johns Hopkins University, Baltimore, MD, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶Brigham and Womens Hospital, Boston, MA, ⁷University of Queensland, Brisbane, Australia, ⁸McMaster University, Hamilton, ON, Canada
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial…
Abstract Number: L11 • ACR Convergence 2021
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid Arthritis: A Retrospective Cohort Study
ELVIRA D'ANDREA¹, Rishi Desai², Mengdong He³, Robert Glynn⁴, Hemin Lee², Michael Weinblatt², Daniel Solomon⁵ and Seoyoung Kim², ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX) is…
Abstract Number: 166 • 2020 Pediatric Rheumatology Symposium
Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones
Margaret Chang¹, Anais Levescot ², Nathan Nelson-Maney ³, Rachel Blaustein ⁴, Kellen Winden ¹, Allyn Morris ⁴, Spoorthi Balu ⁴, Alexandra Wactor ⁴, Kevin Wei ⁵, Lauren Henderson ⁶, Rachael Clark ⁴, Deepak Rao ⁴, Robert Fuhlbrigge ⁷ and Peter Nigrovic ⁸, ¹Boston Children's Hospital, Boston, ²Boston, ³, ⁴Brigham and Women's Hospital, Boston, ⁵BWH, Boston, ⁶Boston Children's Hospital, Watertown, Massachusetts, ⁷University of Colorado, Aurora, ⁸Boston Children's Hospital, Boston, Massachusetts
Background/Purpose: Resident memory T cells (TRM) are site-specific memory T cells that take up long-term residence in peripheral tissues and aid in pathogen defense. Dysregulated…
Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Naizhuo Zhao ¹, Audrey Smargiassi ², Marianne Hatzopoulou ³, Ines Colmegna ⁴, Marie Hudson ⁵, Marvin Fritzler ⁶, Philip Awadalla ⁷ and Sasha Bernatsky⁸, ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²University of Montreal, Montreal, Canada, ³University of Toronto, Toronto, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁷Ontario Institute for Cancer Research, Toronto, Canada, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
Abstract Number: L12 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Evgeniy Nasonov ¹, Saeed Fatenejad ², Elena Korneva ³, Diana Krechikova ⁴, Alexey Maslyansky ⁵, Tatyana Plaksina ⁶, Marina Stanislav ⁷, Rumen Stoilov ⁸, Tamara Tyabut ⁹, Sergey Yakushin ¹⁰, Elena Zonova ¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, Charlotte, North Carolina, ³R-Pharm, Moscow, Russia, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, ⁵SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, ⁶SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁹Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, ¹²Stanford University, Stanford, CA
Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
Abstract Number: 49 • 2019 ACR/ARP Annual Meeting
Towards a Single Cell Portrait of Rheumatoid Arthritis – Development of a Single Cell Multiomics Pipeline for Phase 2 of the Accelerating Medicine Partnership (AMP) – RA Network
Kevin Wei¹, Anna Helena Jonsson ¹, Fan Zhang ², Aparna Nathan ³, Joseph Mears ², Gerald Watts ², Zhu Zhu ², ilya Korsunsky ², Laura Donlin ⁴, Deepak Rao ², Andrew Filer ⁵, Accelerating Medicine Partnership (AMP) ⁶, Brendan Boyce ⁷, Ellen Gravallese ⁸, V. Michael Holers ⁹, Larry Moreland ¹⁰, Peter Gregersen ¹¹, Vivian Bykerk ¹², Jennifer Anolik ⁷, Soumya Raychaudhuri ² and Michael Brenner ¹³, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Hospital For Special Surgery, New York, NY, ⁵Institute of Inflammation and Ageing College of Medical and Dental Sciences University of Birmingham, Birmingham, United Kingdom, ⁶Brigham and Women's Hospital, Boston, ⁷University of Rochester Medical Center, Rochester, NY, ⁸University of Massachusetts Medical School, Worcester, MA, ⁹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ¹⁰University of Pittsburgh, PITTSBURGH, PA, ¹¹Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Hospital for Special Surgery, New York City, NY, ¹³Brigham and Women’s Hospital:, Boston
Background/Purpose: The goal of the Accelerating Medicines Partnership (AMP) program is to study synovial tissue from individuals with rheumatoid arthritis (RA) using high-dimensional analyses. During…
Abstract Number: 181 • 2019 ACR/ARP Annual Meeting
Prevalence of Renal Impairment in a US Rheumatoid Arthritis Population
Jon Giles¹, Lee Simon ², Janet Pope ³, Jim Paik ⁴, Michael Grabner ⁵, Amanda Quebe ⁶, Carol Gaich ⁶, Claudia Salinas ⁶ and Jeffrey Curtis ⁷, ¹Division of Rheumatology, Columbia University, New York, NY, ²SDG LLC, Cambridge, ³Western University, London, ON, Canada, ⁴Eli Lilly & Company, Indianapolis, IN, ⁵HealthCore, Inc., Wilmington, DE, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Clinical management of rheumatoid arthritis (RA) must consider patient renal function, particularly for medications that rely on renal clearance and require dose adjustment or…
Abstract Number: 252 • 2019 ACR/ARP Annual Meeting
Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients
Aliza Karpes ¹, Zhigang Duan ², Hui Zhao ², Lincy Lal ³, Wenyaw Chan ³, Maria E. Suárez-Almazor ⁴, Sharon Giordano ², John Swint ³ and Maria Lopez-Olivo², ¹School of Public Health, The University of Texas Health Science Center at Houston, Dallas, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, ⁴Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX
Background/Purpose: To evaluate the sequences of therapeutic drugs used by rheumatoid arthritis (RA) patients whose initial tumor necrosis factor inhibitor (TNFi) therapy failed, as well…
Abstract Number: 439 • 2019 ACR/ARP Annual Meeting
Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection
Daniel Furst¹, George Wan ², Jingyu Liu ³, Julie Zhu ³, Laura Bartels-Peculis ³, Mary Panaccio ³ and Roy Fleischmann ⁴, ¹University of California, Los Angeles, CA, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder characterized by progressive inflammation and irreversible joint damage. Treatment of active disease includes disease-modifying anti-rheumatic drugs (DMARDs)…
Abstract Number: 464 • 2019 ACR/ARP Annual Meeting
Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage
Takayoshi Owada¹, Kazuhiro Kurasawa ¹, Yuta Takamura ¹, Toshiyuki Miyao ¹, Ayae Tanaka ¹, Ryutaro Yamazaki ¹, Satoko Arai ¹, Reika Maezawa ¹ and Masafumi Arima ¹, ¹Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi, Japan
Background/Purpose: A number of studies have investigated the association between serum RF and joint damage in early and established RA patients, and positive and high-titer…
Abstract Number: 502 • 2019 ACR/ARP Annual Meeting
Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naïve Patients with Early Rheumatoid Arthritis
Mohammad Movahedi ¹, Deborah Weber ¹, Pooneh Akhavan ² and Edward Keystone³, ¹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada, ³Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Progressive rheumatoid arthritis (RA) is responsible for disabilities in this patient population, characterized by radiographic joint damage. Achieving low disease activity (LDA) in RA…
Abstract Number: 551 • 2019 ACR/ARP Annual Meeting
Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis
Martin Bergman¹, Yoshiya Tanaka ², Gustavo Citera ³, Sami Bahlas ⁴, Mira Ali ⁵, Sebastian Meerwein ⁶, Yanna Song ⁷ and Vibeke Strand ⁸, ¹Drexel University College of Medicine, Stockholm, Sweden, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁴Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁵AbbVie Inc., North Chicago, IL, USA, North Chiacgo, ⁶AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁸Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Upadacitinib (UPA) is an oral reversible JAK inhibitor engineered for greater selectivity for JAK1 vs JAK2, JAK3, and TYK2, and is currently being assessed…
Abstract Number: 850 • 2019 ACR/ARP Annual Meeting
Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Alexandre Sepriano¹, Andreas Kerschbaumer ², Josef Smolen ², Désirée van der Heijde ¹, Maxime Dougados ³, Ronald F Van Vollenhoven ⁴, Iain McInnes ⁵, Johannes Bijlsma ⁶, Gerd Burmester ⁷, Maarten de Wit ⁸, Louise Falzon ⁹ and Robert B.M. Landewé ¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Medical University of Vienna, Vienna, Austria, ³Cochin Hospital, Paris, France, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁷Charité—University Medicine Berlin, Berlin, Germany, ⁸Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁹Northwell Health, New York, ¹⁰Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: To assess the most recent safety-data of synthetic (s) and biological (b)DMARDs to inform the 2019 update of the EULAR recommendations for the management…

1
2
3
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].